There is reason for cautious optimism that HIV regimens can be simplified without sacrificing safety or efficacy, all the better to treat increasingly younger and fitter patients who are going on from an HIV diagnosis to leading long and healthy lives.
Initial 48-week data from the phase 3 trials, GEMINI 1 and 2, comparing dolutegravir (Tivicay, ViiV Healthcare) plus lamivudine (Epivir, ViiV Healthcare) (DTG+3TC) with dolutegravir plus two nucleoside reverse transcriptase inhibitors,